Organelle Crosstalk and Metabolic Reprogramming in Idiopathic Pulmonary Fibrosis: Mechanisms and Therapeutic Implications Authors: Yining Zhang, Ling Teng, Limin Gong, Yuandong Fu, Minyi Qian Published: 2026 ABSTRACT ABSTRACTIdiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease of unknown cause, marked by excessive deposition of extracellular matrix (ECM) components such as collagen. This pathological accumulation results in progressive destruction of the lung architecture and ultimately leads to respiratory failure. Growing evidence indicates that dysfunction across multiple cell types is an important driver of IPF. Nevertheless, its underlying pathobiology remains incompletely understood. The normal integrity of organelles is critical for cellular function, and in different IPF lung cells, such as alveolar epithelial cells (AECs), fibroblasts, and macrophages, we found dysfunctional development of key organelles and metabolic reprogramming changes driving malignant progression of pulmonary fibrosis. This review summarizes the contributions of key organelles—mitochondria, the endoplasmic reticulum, lysosomes, and peroxisomes—and functional changes in metabolic reprogramming during IPF progression. We further clarify the core mechanisms of how inter‐organelle network disruptions drive fibrosis, with the goal of identifying critical organelle nodes to disrupt pathogenic metabolic reprogramming and ultimately provide a rationale for developing new treatments. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease characterized by excessive extracellular matrix (ECM) deposition. IPF presents typical clinical features such as insidiously progressive dyspnea, refractory chronic cough, and worsening exercise tolerance. Ultimately, it results in destruction of lung architecture and impaired gas exchange [1]. The pathogenesis of IPF involves complex interactions among multiple cell types, including myofibroblasts, alveolar epithelial cells (AECs), and macrophages. Recent studies indicate that metabolic reprogramming or dysregulation of these cells exerts their profibrotic effects through pathological mechanisms such as autophagy, apoptosis, senescence, and inflammatory responses, ultimately leading to the development of pulmonary fibrosis [2]. Fibroblasts are activated and differentiate into myofibroblasts, which secrete excessive ECM components such as collagen. This process is driven by pro‐fibrotic mediators such as transforming growth factor‐beta (TGF‐β) and platelet‐derived growth factor (PDGF). AECs, particularly alveolar type II (AT2) cells, play a crucial role in maintaining lung homeostasis. Repeated injury to AECs can lead to metabolic dysfunction, impaired repair, epithelial apoptosis and epithelial–mesenchymal transition (EMT) [3]. Additionally, dysregulated epithelial cells interact with interstitial, immune, and endothelial cells through various signaling mechanisms, activating fibroblasts and myofibroblasts and causing fibrous content to accumulate in the lungs [4]. Currently, the U.S. Food and Drug Administration (FDA) has approved pirfenidone, nintedanib, and nerandomilast for the treatment of IPF. Pirfenidone exhibits anti‐fibrotic, anti‐inflammatory, and antioxidant activities by downregulating TGF‐β/Smad signaling to inhibit inflammatory cytokines and upregulating erythroid 2‐related factor 2 (NRF2) for antioxidation, thereby mitigating AEC injury and suppressing matrix deposition. Nintedanib is a tyrosine kinase inhibitor that antagonizes PDGF, fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) receptors and blocks the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) and rat sarcoma (Ras)/mitogen‐activated protein kinase (MAPK) signaling pathways to inhibit fibroblast differentiation. However, these two medications can only slow the decline in pulmonary function and cannot fundamentally halt disease progression [5]. Nerandomilast, approved in October 2025 [6], selectively inhibits phosphodiesterase 4B (PDE4B), thereby continuously elevating intracellular cyclic adenosine monophosphate (cAMP) levels and activating protein kinase A (PKA), which corrects the metabolic reprogramming of IPF fibroblasts at the source [7]. Nevertheless, its long‐term efficacy and real‐world safety remain to be established. Given the limitations of current therapies, a thorough elucidation of the molecular mechanisms underlying IPF is of paramount importance for identifying novel therapeutic targets. Recently, growing evidence indicates that metabolic reprogramming is a central mechanism in many diseases, including IPF. Notably, subcellular organelles play an important role in this process, as the maintenance of homeostasis in mammalian cells depends on the coordinated function of subcellular organelles in regulating the interactions of multiple signaling pathways. Metabolic reprogramming is a process where glycolysis, oxidative phosphorylation and amino acid processes alter to fulfill the energy needs and biosynthetic needs of cells, whereby subcellular organelles, such as mitochondria, play a key role in that process. The abnormality of these subcellular organelles which include impaired mitochondrial oxidative phosphorylation (OXPHOS), disruption of peroxisomal lipid metabolism, endoplasmic reticulum (ER) stress, and defects of lysosomal autophagy contribute to the progression of fibrosis. Herein, we provide a comprehensive overview of the current understanding of subcellular organelle dysfunction in IPF, with a particular focus on how organellar damage drives metabolic reprogramming in key pulmonary cell types. We systematically discuss the distinct roles of mitochondria, ER, lysosomes, and peroxisomes in the initiation and progression of fibrosis, and critically evaluate emerging therapeutic strategies aimed at restoring organelle homeostasis, including antioxidant delivery, mitochondrial transfer, ER stress relief, lysosomal enhancement, and peroxisomal modulation. By synthesizing recent advances and identifying unresolved questions, this review seeks to offer new insights into the pathogenic mechanisms of IPF and to highlight potential organelle‐targeted interventions that may pave the way for more effective treatments for this devastating disease. Multi‐Organelle Dysfunction in Pulmonary Fibrosis Mitochondria Mitochondria are dynamic double‐membrane organelles that generate the majority of cellular ATP through OXPHOS, which is the center of energy metabolism. Various signal transduction pathways are joined and interact within mitochondria, regulating processes of mitochondrial biogenesis, fusion/fission balance, electron transport chain (ETC) activity, preservation and repair of mitochondrial DNA (mtDNA), and mitophagy [8]. When mitochondrial homeostasis is disrupted, OXPHOS becomes impaired, leading to reactive oxygen species (ROS) accumulation and initiating a vicious cycle of escalating dysfunction (Figure 1). Moreover, the expression of fusion proteins, including mitofusin 1 (MFN1), mitofusin 2 (MFN2), and optic atrophy protein 1 (OPA1), is downregulated, whereas that of division proteins, such as dynamin‐related protein 1 (DRP1) and mitochondrial fission 1 protein (FIS1), is abnormally upregulated, driving excessive mitochondrial fragmentation and loss of oxidative capacity [9]. These fragmented mitochondria serve as the primary source of ROS. Mitochondrial dysfunction promotes the development of IPF in different types of lung cells by metabolic dysregulation and pro‐fibrotic signaling. Multiple organelle mechanisms drive the pathogenesis of idiopathic pulmonary fibrosis (IPF). The feature of mitochondrial dysfunction is an imbalance in fission/fusion, mtDNA damage, reduced electron transport chain (ETC) activity, and elevated reactive oxygen species (ROS). Peroxisomal function is impaired via suppression of peroxisome proliferator‐activated receptor gamma (PPARγ) and its target molecules by upregulation of DNA methyltransferase 1 (DNMT1)/DNA methyltransferase 3a (DNMT3a) and transforming growth factor‐beta (TGF‐β)/Smad signaling. Endoplasmic reticulum (ER) stress is initiated by the transmembrane sensors protein kinase RNA‐like endoplasmic reticulum kinase (PERK), inositol‐requiring enzyme 1 alpha (IRE1α), and activating transcription factor 6 (ATF6), leading to a sustained unfolded protein response (UPR). Lysosomal autophagy can be disrupted by factors such as BCL2‐associated athanogene 3 (BAG3), TGF‐β, and silica nanoparticles (SiNPs). These organelle disturbances collectively promote alveolar epithelial type 2 cell (AT2) apoptosis, epithelial–mesenchymal transition (EMT), extracellular matrix (ECM) deposition, inflammatory activation, and finally drive IPF progression. AT2 Cells: Early Mitochondrial Collapse and Damage‐Associated Molecular Patterns (DAMPs) Release Mitochondrial dysfunction in AECs is a key early event that triggers the fibrotic cascade. Under bleomycin‐induced damage, these cells exhibit reduced oxidative phosphorylation capacity and suppressed glycolytic flux, resulting in an inability to meet the energy demands for phospholipid and surfactant protein synthesis. This is manifested by reduced expression of the glucose transporter 1 (GLUT1), restricted exchange of intermediate products in the tricarboxylic acid (TCA) cycle, and a significant decrease in extracellular acidification rate (ECAR), collectively leading to ATP depletion and extensive DNA damage [10]. mtDNA damage, a characteristic feature in pulmonary fibrosis, promotes AT2‐cell apoptosis. Mitochondrial enlargement and morphological changes occur in AT2 cells in IPF, with impaired activity of electron transport chain complexes I and IV. This phenotype is associated with reduced expression of phosphatase and tensin homolog (PTEN)‐induced putative kinase 1 (PINK1), a mitochondrial autophagy regulatory factor induced by PTEN. Loss of PINK1 leads to mitochondrial dysfunction, upregulation of senescence markers cyclin‐dependent kinase inhibitor 2A (p16) and cyclin‐dependent kinase inhibitor 1A (p21), and elevated TGF‐β expression levels, which directly promote fibrosis [11]. Simultaneously, the inhibition of the PINK1/Parkin pathway provokes mitophagy defects, leading to the formation of damaged mitochondria, an excess of released ROS and pro‐fibrotic factors. The accumulation of mitochondrial ROS in epithelial cells not only perpetuates cellular intrinsic damage but also triggers the release of DAMPs, such as mitochondrial DNA and cardiolipin, into the extracellular space, thereby establishing a paracrine signaling axis that activates adjacent fibroblasts and immune cells. Fibroblasts: The Pro‐Inflammatory Effects of ROS and Metabolites The transition of fibroblasts to an activated myofibroblast phenotype can be driven by mitochondrial dysfunction. During fibroblast activation into a myofibroblast phenotype, their mitochondria often exhibit enhanced glycolysis. This leads to the accumulation of damaged mitochondria, a shift toward anaerobic glycolysis, and lactate buildup, thereby promoting fibroblast activation and matrix deposition [12]. High levels of mitochondrial ROS, generated as a result of impaired respiratory chain function, can trigger pro‐inflammatory responses, including nuclear factor‐κB (NF‐κB), tumor necrosis factor α (TNF‐α), nucleotide‐binding oligomerization domain‐like receptor protein 3 (NLRP3) inflammasome, and activating protein‐1 (AP‐1) [13]. This results in sustained activation of TGF‐β signaling, which stabilizes the myofibroblast phenotype. Acetyl‐CoA and α‐ketoglutarate are essential cofactors for histone acetylation and DNA demethylases, respectively. When these metabolites undergo regional depletion due to mitochondrial dysfunction, the promoter regions of antifibrotic genes experience hypermethylation, while pro‐fibrotic genes remain in an active acetylated state, potentially driving the expression program of pro‐fibrotic genes [14]. The production of fumarate and the reverse reaction catalyzed by succinate dehydrogenase, leading to the accumulation of succinate in fibrotic lungs and myofibroblasts, are common metabolic features of pulmonary fibrosis. Excess succinate results in the stabilization and activation of hypoxia‐inducible factor 1 alpha (HIF‐1α), which in turn upregulates glycolysis and downregulates fatty acid oxidation (FAO), thereby promoting the development of pulmonary fibrosis [15]. Furthermore, abnormal mitochondrial calcium handling in activated fibroblasts, driven by altered expression of the mitochondrial calcium uniporter (MCU) and its regulatory subunits, contributes to the sustained activation of calcineurin and nuclear factor of activated T cells (NFAT) signaling, further reinforcing myofibroblast gene expression programs. Dysfunctional mitochondria can propagate between cell types via extracellular vesicles or tunneling nanotubes, promoting the metabolic and secretory phenotype of fibroblasts that receive these mitochondria to undergo fibrosis. Macrophages: M2 Reprogramming and Autophagy Deficiency In macrophages, mitochondrial dysfunction fundamentally alters the immune response. Mitochondrial dysfunction reprograms macrophages into a pro‐fibrotic M2 phenotype through multiple interconnected mechanisms in fibrotic lungs [16]. Studies have shown that ferroptosis induces apoptosis of immune cells, leading to the release of mitochondrial DNA (mtDNA) and DAMPs in macrophages, thereby activating inflammatory pathways, including the NLRP3 inflammasome and cyclic GMP‐AMP synthase (cGAS)‐stimulator of interferon genes (STING) pathway. In mitochondria, dysfunctional mtDNA leakage from macrophage mitochondria serves as an important source of DAMPs, creating a DAMP‐enriched microenvironment. This enhances the maturation and secretion of type I interferons and pro‐inflammatory cytokines IL‐1β and IL‐18, which reinforce the profibrotic macrophage phenotype. Itaconate is an immune‐regulatory metabolite produced by the mitochondrial enzyme aconitate decarboxylase 1 (ACOD1) in inflammatory macrophages. The upregulation of the itaconate synthetic machinery has been linked to mitochondrial oxidative stress. In IPF, the ACOD1/itaconate pathway is markedly dysregulated. Itaconate synthesis is suppressed in bronchoalveolar lavage fluid (BALF) alveolar macrophages from IPF patients, and genetic deletion of Acod1 leads to aggravated fibrosis in murine models. Beyond its role in macrophages, itaconate can directly act on fibroblasts to reverse their metabolic reprogramming by decreasing both proliferation and wound healing capacity [17]. Furthermore, defects in mitochondrial autophagy in macrophages impair their ability to handle the increased metabolic burden associated with phagocytosis of apoptotic cells and debris, exacerbating the production of reactive oxygen species. This not only drives macrophage senescence but also promotes the release of pro‐fibrotic extracellular vesicles containing oxidized mitochondrial DNA. These vesicles activate pattern recognition receptors in neighboring structural cells, such as Toll‐like receptor 9 (TLR9), amplifying fibrotic signals throughout the lung. Endoplasmic Reticulum The ER is a central organelle for protein synthesis, folding, modification, and quality control in eukaryotic cells. Its homeostatic operation relies on an elaborate network of molecular chaperones, folding enzymes, and degradation pathways such as ER‐associated degradation (ERAD), which together ensure that only correctly folded proteins are transported to their destinations. However, ER stress can be triggered by disrupted protein folding and post‐translational modifications, which is a key driver of disease onset and progression. Concurrently, misfolded proteins accumulate in the ER, stimulating the cell to rebuild its protective pathways for the ER, known as the unfolded protein response (UPR) [18]. UPR can restore ER homeostasis by reducing protein synthesis and promoting the degradation of misfolded proteins. However, if ER stress is chronically overloaded, UPR will fail to effectively alleviate the stress, potentially leading to severe cellular dysfunction. Protein kinase RNA‐like endoplasmic reticulum kinase (PERK), inositol‐requiring enzyme 1 alpha (IRE1α), and activating transcription factor 6 (ATF6) are the three primary signaling pathways in the UPR. The immunoglobulin‐binding protein (BiP) binds to them to maintain ER homeostasis, but prolonged stress causes BiP dissociation, which activates these transmembrane proteins to release pro‐fibrotic signals, leading to apoptosis, inflammation, and fibrosis (Figure 1). Metabolic reprogramming is also closely involved. Metabolites such as saturated fatty acids, cholesterol, and arachidonic acid all participate in the progression of IPF by ER stress, apoptosis, and the expression of pro‐fibrotic biomarkers [19]. AT2 Cells: Surfactant Protein Misfolding and UPR‐Driven Apoptosis AT2 cells are the primary sites for the synthesis and secretion of pulmonary surfactants. They synthesize and secrete large quantities of surfactant proteins B and C (SP‐B, SP‐C) and phospholipids, which are produced on the rough ER as precursors (pro‐SP‐B, pro‐SP‐C) [20]. These proteins are then transported from the ER to the Golgi apparatus and ultimately enter the lamellar bodies for storage and secretion. This complex processing pathway makes AT2 cells particularly sensitive to ER homeostasis. In IPF, one of the earliest and most significant pathological changes is the dysregulation of surfactant synthesis and transport. Mutations in surfactant protein genes, notably SFTPC, cause misfolding of pro‐SP‐C, leading to its accumulation as aggregates in the ER lumen. Meanwhile, the decline in ERAD function associated with aging also reduces the cell's ability to clear misfolded proteins [21]. The ultimate outcome is the extensive accumulation of misfolded surfactant proteins within the ER lumen, exceeding the folding processing capacity of the molecular chaperone network, thereby triggering prolonged ER stress. While the UPR initially restores ER homeostasis via ATF6 and IRE1α‐X‐box binding protein 1(XBP1), prolonged unresolved stress switches signaling to the IRE1α‐tumor necrosis factor receptor‐associated factor 2 (TRAF2) and PERK‐C/EBP homologous protein (CHOP) axes, which upregulate pro‐apoptotic proteins BCL‐2‐associated X protein (BAX) and caspase‐12 to promote AT2‐cell apoptosis. ER stress inhibitors can effectively inhibit AT2‐cell apoptosis and pulmonary fibrosis [22]. Loss of AT2 cells depletes epithelial progenitors, impairs regeneration, and exposes the basement membrane, thereby driving fibroblast activation and aberrant ECM deposition [23]. Even without immediate apoptosis, chronic low‐level UPR promotes secretion of inflammatory factors that drive IPF progression. The interplay between TGF‐β1, HIF‐1α, and the ER stress/UPR signaling pathways plays a key role in inhibiting the wound closure capability of AECs. ER stress–activated HIF‐1α induces TGF‐β1 release, which reciprocally amplifies HIF‐1α signaling and worsens ER stress, perpetuating epithelial damage in IPF [24]. Moreover, TGF‐β also initiates UPR via ER stress and causes fibrotic changes through the protein kinase C substrate 80K‐H (PRKCSH)/IRE and PERK/growth arrest and DNA damage‐inducible protein 34 (GADD34)/CHOP pathways. Meanwhile, the ER protein Nogo‐B can regulate the activity of matrix metalloproteinase 14 (MMP14) to promote the maturation of the TGF‐β1 precursor protein. Finally, free TGF‐β1 can be released [25]. Free TGF‐β1 can induce the epithelial‐mesenchymal transition (EMT) of epithelial cells in the development of IPF, which is a key step in the activation of the TGF‐β pathway. Cyclic adenosine monophosphate (cAMP) is a significant second messenger in lung epithelial cells, activating phosphorylation of protein kinase A (PKA). ER stress can activate NLRP3 inflammasome in AT2 cells to promote fibrosis, while the cAMP/PKA pathway counteracts this by repressing AT2 cells pyroptosis [26]. ER stress simultaneously activates these two pathways in AT2 cells, establishing a balancing relationship. Fibroblasts: ER Protein Dysregulation and Disrupted Collagen Homeostasis ER stress can mediate the differentiation of fibroblasts into myofibroblasts. To produce large amounts of collagen, myofibroblasts expand their ER and construct the extracellular matrix through the synergistic action of two proteins, FK506‐binding protein 10 (FKBP10) and heat shock protein 47 (Hsp47). Hsp47 is a collagen‐specific molecular chaperone that assists in the proper folding of procollagen within the ER. FKBP10 can bind to Hsp47 during this process, promoting the folding of procollagen into mature collagen molecules. There are numerous protein components in the ER playing important roles in IPF. Reticulon 3 (RTN3) is an ER protein which promotes hydroxyproline expression and collagen synthesis. Chemoattractant receptor‐homologous molecule (CRTH2), which is expressed on T helper 2 (Th2) cells, is a novel RTN3‐interacting protein. CRTH2 can be transported to the ER membrane of fibroblasts and bind to the collagen mRNA recognition motif of La ribonucleoprotein 6 (LARP6) to promote the degradation of collagen mRNA [27]. In fibroblasts, reduced RTN3 decreases the binding sites available for CRTH2 in the ER of lung fibroblasts and lowers CRTH2 levels, thus reducing binding to LARP6, and subsequently decreasing collagen mRNA degradation in lung fibroblasts. B‐cell lymphoma 2 (BCL‐2) is an important regulatory protein on the IRE1α–XBP1 pathway, which downregulates IRE1α activation by splicing the mRNA of the transcription factor XBP1, thus alleviating ER stress and IPF. BCL‐2 can also bind BCL‐2‐associated X protein (BAX) in fibroblasts, disrupting the physical binding of BAX to IRE1α and reducing IRE1α activation [28]. In addition to ER‐associated protein folding, proteasomal control of redox regulators contributes to fibroblast activation. TGF‐β1 promotes ubiquitin‐dependent degradation of thioredoxin‐interacting protein (TXNIP), whereas USP13‐mediated deubiquitination stabilizes TXNIP and attenuates Smad2/3 phosphorylation and fibronectin expression in lung fibroblasts [29]. Macrophages: ER Stress Governs M1/M2 Phenotypic Polarization Although all three pathways play important roles, the IRE1α–XBP1 pathway is prominently involved in macrophage ER stress [30]. Activated XBP1s directly bind to the promoters of IL‐6, TNF‐α, and IFN‐β1 genes in macrophages, indicating that XBP1 in macrophages may exert a negative role in pulmonary fibrosis by regulating multiple genes. Furthermore, ER stress can significantly affect the efferocytosis function of macrophages. ER stress sustains the M1‐like phenotype of interstitial macrophages (IMs). This pro‐inflammatory state in the context of IPF is evidenced by their elevated expression of pro‐IL‐1β and TNF‐α [31]. Furthermore, CRTH2 drives macrophage differentiation towards M2 type by upregulating CD206 expression. However, RTN3 gene deletion significantly exacerbates this effect. Subsequently, CRTH2 cannot bind to RTN3 and simultaneously inhibits autophagic vesicle formation, which prevents CRTH2 from being effectively degraded via the autophagy pathway. After macrophages exhibit M2 type, they secrete various cytokines such as IL‐6 and TNF‐α, with IL‐1α being particularly significant in the early stages of IPF [32]. Lysosome Lysosomes are membrane‐bound cell organelles that store different acid hydrolases, thereby ensuring cellular homeostasis by breaking down macromolecules, clearing damaged organelles and recycling the metabolites. Damage to lysosomes themselves and excessive activation of autophagy can both negatively impact cells. Autophagy defends against oxidative stress by degrading and recycling damaged macromolecules and dysfunctional organelles, thereby reducing ROS‐induced damage. Dysregulated autophagic flux, whether excessive or deficient, promotes IPF progression. AT2 Cells: Lysosomal Rupture and Apoptotic Surfactant Disruption Lysosomes are highly active in AT2 cells. After impairment of lysosomal phagocytic function, accumulation of undegraded abnormal proteins and organelles occurs, which activates the caspase‐3 apoptotic pathway, induces apoptosis of AT2 cells, and releases pro‐inflammatory and pro‐fibrotic factors, driving the progression of IPF [33]. For example, silica nanoparticles (SiNPs), after being phagocytosed by AECs, disrupt the acidic environment of lysosomes to impair their degradation functions. Subsequently, the accumulation of abnormal proteins and organelles triggers cellular stress responses and activates the caspase‐3 apoptotic pathway. Similarly, knockout of the autophagy‐related protein LC3B, which is also localized in AECs, leads to the accumulation of syntaxin 17 (a key mediator of autophagosome‐lysosome fusion) in AT2 cells. Simultaneously, cathepsin A also cannot be effectively packaged and degraded. It accumulates intracellularly and causes AT2 cells death [34]. Consequently, this disruption results in increased apoptosis, impaired surfactant homeostasis, and lysosomal stress (Figure 1). Fibroblasts: Impaired Autophagic Flux Insufficient acidification is a characteristic of fibroblast lysosomes in IPF. Studies have observed cholesterol accumulation in fibroblasts of IPF patients, which may be due to reduced lysosomal acidification and impaired transport of cholesterol to peroxisomes. Excessive cholesterol accumulation, as stated previously, can lead to inflammasome activation and cytokine secretion. Additionally, multiple lysosomal defects in IPF fibroblasts, including reduced enzyme processing, substrate degradation, and autophagosome clearance, collectively diminish catabolic function. Ultimately, these promote fibroblast activation and ECM deposition, facilitating progression of pulmonary fibrosis. BCL2‐associated athanogene 3 (BAG3), as a heat shock protein 70 (HSP70) chaperone, can collaborate with the heat shock protein family A member 8 (HSPA8)‐STIP1 homology and U‐box containing protein 1 (STUB1) complex to mediate ubiquitination of abnormal proteins. Subsequently, abnormal proteins can be targeted for degradation in lysosomes via the sequestosome‐1 (SQSTM1/p62) pathway. Moreover, BAG3 overexpression and filamin C (FLNC) accumulation in IPF fibroblasts reflect impaired autophagy, which activates PI3K/AKT/mTOR signaling to promote proliferation and apoptosis resistance [35]. Targeting the BAG3‐ubiquitination autophagy axis or restoring lysosomal degradation capacity may become a new direction for IPF treatment. The aberrantly high expression of osteoglycin (OGN) inhibits lysosomal degradation, stabilizing integrin αv and enhancing its binding to TGF‐β latency‐associated peptide (LAP), thereby activating TGF‐β. This drives myofibroblast differentiation and collagen deposition via Smad2/3 phosphorylation [36]. It has been reported that TGF‐β1 can also upregulate LINC00941 by activating the transcription factor 3 (ATF3). LINC00941 forms a complex with the RNA‐binding protein ELAV like RNA binding protein 1 (ELAVL1) that blocks autophagosome‐lysosome fusion, thereby impairing autophagic flux. Concurrently, overexpression of LINC00941 drives fibroblast conversion to myofibroblasts, promotes collagen and fibronectin secretion, and finally enhances IPF [37]. Ras‐associated binding 11 (Rab11) is a small GTPase that regulates endocytic recycling, returning membrane receptors to the cell surface to sustain signaling. The fibroblast marker protein asporin (ASPN) promotes Rab11‐mediated recycling of TGF‐β receptor I (TGF‐βRI) to the cell surface while reducing its lysosomal degradation, thereby sustaining TGF‐β/Smad signaling and driving myofibroblast differentiation [38]. Macrophages: Defective Efferocytosis and DAMPs Vicious Cycle Lysosomes are the most prominent organelles in macrophages, and the degradation of engulfed material during efferocytosis in macrophages entirely depends on lysosomes. In IPF macrophages, lysosomal dysfunction leads to ineffective degradation of ingested apoptotic cells. Partially degraded apoptotic bodies accumulate intracellularly, eventually causing macrophage rupture and massive leakage of contents, which is the cause of release of DAMPs such as ATP, high mobility group box 1 (HMGB1), and mtDNA. HMGB1 can participate in the inhibitory process of efferocytosis by interacting with receptors on the surface of macrophages or phosphatidylserine on apoptotic cell membranes [39]. Macrophage lysosomes are the most critical inducers of inflammasome activation within the lung. Lysosomal rupture triggers activation of the NLRP3 inflammasome in macrophages [40]. Activation of NLRP3 generates large amounts of IL‐1β, enhances TGF‐β signaling, and promotes fibrosis progression [41]. Additionally, DAMPs such as mtDNA continuously stimulate alveolar macrophages, inducing their transformation into the M2 phenotype and expression of profibrotic factors such as TGF‐β, rather than executing normal phagocytic functions. Uncleared apoptotic cells, upon further rupture, release more DAMPs, forming a vicious cycle. The task of systemic iron recycling is primarily undertaken by macrophages of the reticuloendothelial system, with alveolar macrophages responsible within the lung. Dysfunction of lysosomal divalent metal transporter 1 (DMT1) and transient receptor potential mucolipin 1 (TRPML1) channels leads to iron retention within lysosomes, and macrophages with iron overload are highly prone to ferroptosis [42]. Peroxisome Peroxisomes are organelles that are involved in lipid metabolism and cellular redox balance. Given the hyperoxic environment of the lung, peroxisomes protect against IPF by clearing excessive ROS, and they also contribute to antiviral immunity, inflammation resolution, and tissue repair. Studies confirm impaired peroxisome occurrence and metabolism in the lungs of IPF patients [43]. Targeting enhanced peroxisomal metabolic function is a promising therapeutic approach to mitigate the long‐term consequences of respiratory diseases. AT2 Cells: Ether Lipid Synthesis and Surfactant Lipid Pool Maintenance Peroxisomes in AT2 cells play an essential role in synthesizing ether lipids, particularly plasmalogens, which constitute a critical lipid component of pulmonary surfactant. These specialized lipids contribute to the unique biophysical properties of surfactant, enabling efficient reduction of alveolar surface tension. Beyond surfactant production, lipid metabolism is intimately involved in maintaining AT2‐cell self‐renewal, as AT2 cells serve as alveolar epithelial progenitors and their regenerative capacity depends on proper lipid homeostasis. Peroxisomes process very long‐chain fatty acids through β‐oxidation, shortening them into medium‐chain fatty acids that are subsequently directed to mitochondria for complete oxidation. This peroxisomal β‐oxidation pathway provides essential precursors for the surfactant lipid pool while simultaneously maintaining overall lipid metabolic balance within AT2 cells. Fibroblasts: PPARγ Activation Counteracts TGF‐β‐Driven Myofibroblast Differentiation Peroxisome proliferation is associated with improved fibrotic responses in human lung fibroblasts. Peroxisome proliferator‐activated receptor gamma (PPARγ) is a ligand‐activated transcription factor that regulates gene expression involved in cell differentiation, apoptosis, and various metabolic processes, especially lipid and glucose homeostasis. Furthermore, PPARγ activation is associated with various anti‐inflammatory and anti‐fibrotic effects. The number of peroxisomes in fibroblasts is reduced in pulmonary fibrosis, primarily due to inhibition of peroxisomal biogenesis factor 13 (PEX13). This can lead to excessive accumulation of ROS, further activating pro‐fibrotic signaling pathways. TGF‐β‐Smad signaling acts on the PPARγ promoter. The TGF‐β‐dependent Smad complex binds to inhibitory element (TIE) and Smad‐binding element (SBE) sequences in the PPARγ promoter. As a result, it suppresses PPARγ at the transcriptional level through deacetylation and indicates that TGF‐β signaling can selectively inhibit PPARγ [44]. Inducing peroxisome proliferation through PPAR activator treatment of IPF fibroblasts can reduce TGF‐β‐induced fibroblast differentiation and collagen production (Figure 1). Macrophages: Lipid Mediator Class Switching and Inflammatory Response After Phagocytosis Macrophages orchestrate inflammation through peroxisomal β‐oxidation, which switches lipid mediator synthesis from pro‐inflammatory leukotrienes and prostaglandins to pro‐resolving lipoxins, resolvins, and protectins. In macrophages that have peroxisomal deficiency, the NLRP3 inflammasome can be activated by undegraded lipid metabolites, leading to the formation of Gasdermin D pore and massive release of IL‐1β. This drives transitional epithelial progenitors to differentiate from AT2 to AT1 cells with high Keratin 8 (KRT8) expression, a recognized driver of persistent inflammation and fibrosis after acute infection [45]. Recent studies have shown that ER stress and mitochondrial dysfunction are also key contributors to the persistence of KRT8+ transitional cells. Notably, as AT2 cells enter this transitional state, they undergo a graded loss of mitochondrial mass and progressive downregulation of AMP‐activated protein kinase (AMPK) and PPAR signaling pathways, which links metabolic and organellar disruption to the accumulation of these pathogenic intermediates [46]. When macrophages phagocytose pathogens, they rapidly activate the protein complex NADPH oxidase 2 (NOX2), generating superoxide anions within the phagosome which can damage the macrophages themselves. Moreover, they promote the activation of PPARγ and increase the expression of liver X receptor alpha (LXR‐α). The upregulation of LXR‐α can further promote the expression of ATP‐binding cassette subfamily A member 1 (ABCA1). ABCA1 has the ability to mediate a positive feedback loop that enhances the PPARγ/LXRα/ABCA1 pathway in macrophages. It leads to inflammatory and fibrotic alterations in alveolar macrophages and lung tissue, thereby modulating bleomycin‐induced inflammation and fibrosis [47]. Injection of apoptotic cells in bleomycin‐treated mice rapidly induces sustained PPARγ expression and upregulates its targets CD36, macrophage mannose receptor (MMR), and angiopoietin 1 (Ang1), thereby enhancing macrophage phagocytic clearance of apoptotic cells. This further activated PPARγ to stimulate hepatocyte growth factor (HGF) production, increase the release of the anti‐inflammatory factor IL‐10, and inhibit TGF‐β‐mediated myofibroblast activation. Moreover, increased interferon gamma (IFNγ) is able to reduce peroxisome synthesis and increase its degradation in macrophages, promoting pulmonary fibrosis progression [45]. Interaction Network of Mitochondria, ER, Lysosomes, and Peroxisomes Cellular organelles do not function in isolation but form a highly integrated network essential for cellular homeostasis. Mitochondria communicate with the ER via mitochondrial‐associated membranes (MAMs), lysosomes receive vesicular cargo from the ER and Golgi, and peroxisomes cooperate with mitochondria and ER in lipid metabolism and ROS detoxification. These interorganelle interactions collectively coordinate energy production, redox balance, protein homeostasis, and cellular responses to stress. Under steady‐state conditions, this network dynamically adjusts organelle function to meet cellular demands. In IPF, however, disruption of these communication hubs propagates dysfunction, exacerbating proteotoxic stress, metabolic failure, and pro‐inflammatory signaling, thereby driving fibrogenesis. MAMs: The ER–Mitochondria–Lysosome Axis in Calcium Signaling, Mitophagy, and Fibrotic Coupling There is a dynamic platform called mitochondria‐associated membranes (MAMs) formed by mitochondria and ER. Sphingolipids, synthesized in the ER, can be transported to mitochondria by MAMs to regulate mitochondrial membrane stability and autophagy levels. Importantly, MAMs participate in regulating inter‐organellar signal communication and facilitating calcium influx into mitochondria. The transport pathways of the MAMs platform are mainly constituted by IP3 receptors (IP3R) and voltage‐dependent anion channels (VDAC). Calcium from the ER enters MAMs via IP3R, crosses VDAC, and is taken up by mitochondria through the MCU complex [48]. In IPF, loss of mitochondrial membrane potential causes PINK1 accumulation on the outer membrane, which recruits Parkin to promote mitophagosome formation. The development of mitophagosomes also starts with the expansion of ER membranes creating phagophores. MAMs are provided by the ER as a platform of autophagosome membranes. The unc‐51‐like kinase 1 (ULK1) complex, activated by the AMPK/mTOR pathway, initiates autophagosome formation on the ER membrane. The phosphatidylinositol 3‐kinase (PI3K) complex is recruited to the ER membrane where it catalyzes production of phosphatidylinositol‐3‐phosphate (PI3P) that facilitates phagophore expansion. The broken damaged mitochondria are particularly identified and wrapped with the PINK1/Parkin route. The PINK1 attaches on the outer mitochondrial membrane, which responds to the recruitment of the Parkin ubiquitin ligase to ubiquitinate mitochondria with damage. Autophagy receptors such as SQSTM1/p62 and optineurin (OPTN) recognize ubiquitination sites, anchoring mitochondria to autophagosomes for lysosomal degradation [49]. This mitochondrial autophagy pathway is abnormally regulated by ER stress in IPF. Upregulated thrombospondin‐1 (TSP‐1) in lung fibroblasts binds CD47 to stimulate ROS production, inducing ER stress and promoting fibrosis [50]. Activating transcription factor 3 (ATF3), an ER stress downstream effector, directly regulates PINK1 expression to control mitophagy [51]. ER stress and abnormal mitochondrial autophagy can be coupled, collectively promoting the progression of pulmonary fibrosis. During mitophagy, autophagosomes fuse with lysosomes to form autolysosomes, a process controlled by soluble N‐ethylmaleimide‐sensitive factor attachment protein receptor (SNARE) proteins and Rab GTPases [52]. SNARE proteins are able to facilitate the binding of autophagosome and lysosome membranes to form complexes. Activated by Rab GTPases, vesicles are transported along microtubules to lysosomes, where hydrolases degrade cargo into amino acids and fatty acids, which are released via lysosomal‐associated membrane protein 1 (LAMP1) for reuse [53]. In conclusion, the ER, mitochondria, and lysosomes form a synergistic network during autophagy. The ER dominates autophagosome initiation, mitochondria transmit damage signals via MAMs, and lysosomes complete material recycling, forming a metabolic closed loop. The development of fibrosis will be alleviated if damaged mitochondria are cleared (Figure 2). Interorganellar communication among mitochondria, endoplasmic reticulum (ER), and lysosomes in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Mitochondria‐associated ER membranes (MAMs) serve as critical signaling hubs, which can facilitate calcium transfer into mitochondria via the mitochondrial calcium uniporter (MCU) and MAM‐resident channels such as inositol 1,4,5‐trisphosphate receptor (IP3R) and voltage‐dependent anion channel (VDAC). Elevated calcium flux promotes the initiation of mitophagy. When mitochondria are damaged, PTEN‐induced putative kinase 1 (PINK1) will accumulate on the outer mitochondrial membrane and recruit Parkin to mediate ubiquitination of damaged organelles. ER can provide membrane components through phagophore formation under the regulation of unc‐51 like autophagy activating kinase 1 (ULK1) and class III phosphoinositide 3‐kinase (PI3K) complexes. Subsequently, autophagosomes can integrate with lysosomes in the process mediated by soluble N‐ethylmaleimide‐sensitive factor attachment protein receptor (SNARE) proteins and Ras‐related protein in brain (Rab) GTPases, which forms autolysosomes to degrade cargo and enable nutrient recycling. This process is impaired in IPF. Peroxisomal Functions and Their Crosstalk With Other Organelles in IPF Peroxisomes are highly dynamic and crucial metabolic organelles that, through crosstalk with mitochondria, the ER, and lysosomes, also participate in the regulation of IPF. Peroxisomes contain catalase and other antioxidant enzymes that can effectively eliminate ROS. Therefore, when peroxisomes are damaged, the excessive ROS generated by mitochondria become difficult to clear, promoting inflammatory injury and the progression of IPF. Peroxisomes can also directly communicate with mitochondria and contribute to cellular lipid metabolism, such as the oxidation of very long‐chain fatty acids (VLCFAs), the synthesis of phospholipids including ether phospholipids and docosahexaenoic acid (DHA). Peroxisomes are responsible for the initial oxidation of very long‐chain fatty acids, which are then taken up by mitochondria to complete thorough degradation for energy production. Fatty acids can act as natural ligands for PPARs, inducing their activation and stimulating mitochondrial biogenesis. Conversely, when peroxisomal function is impaired, lipid metabolic waste disrupts mitochondrial function and can accumulate in the ER, triggering ER stress. Ether phospholipids derived from peroxisomes are crucial for maintaining the fluidity of MAMs membranes. Their deficiency can indirectly disrupt mitochondrial calcium homeostasis and the proper expansion of autophagosome membranes, directly affecting the lipid composition of the ER membrane and consequently the integrity of MAMs derived from it. A dynamic membrane contact between peroxisomes and lysosomes, mediated by the binding of lysosomal synaptotagmin VII (Syt7) to the lipid phosphatidylinositol 4,5‐bisphosphate (PI(4,5)P2) on the peroxisomal membrane, facilitates non‐vesicular cholesterol transport from lysosomes to peroxisomes. This process is crucial for maintaining cholesterol homeostasis in the lysosomal membrane and normal lysosomal autophagic function. Cholesterol overload inhibits lysosomal exocytosis and induces membrane permeabilization, releasing lysosomal enzymes that activate NLRP3 inflammasomes and IL‐1β secretion, thereby disrupting lysosomal homeostasis and exacerbating fibrosis [54]. Pulmonary Fibrosis and Organelle Metabolic Reprogramming Carbohydrate Metabolic Reprogramming Drives IPF Glucose metabolism constitutes a fundamental hub of cellular energetics and biosynthesis, encompassing glycolysis, the TCA cycle, and the pentose phosphate pathway. Under homeostatic conditions, these pathways are tightly regulated to generate ATP, supply biosynthetic precursors for amino acids, nucleotides, and lipids, and maintain redox balance through the production of NADPH. However, in pulmonary fibrosis, glycometabolism undergoes significant alterations (Table 1). Table 1Major organelles involved in metabolic reprogramming during idiopathic pulmonary fibrosis and their underlying molecular mechanisms.Organellemolecular mechanismsMetabolic reprogramming featuresProfibrotic consequencesRepresentative referencesMitochondriaIL‑11 → ERK → HIF‑1α ↑ → HK2, LDHA ↑Enhanced glycolysisPromotes FMT and collagen deposition in CS‑induced IPF[55]mTOR ↑ → ATF4 translation ↑ → SHMT2, ASNS upregulationEnhanced serine/glycine and asparagine synthesis, disrupted amino acid homeostasisde novo glycine synthesis supplies collagen precursors, promoting ECM deposition[56, 57]TGF‐β1 → SMAD3/p38 MAPK → GLS1Enhanced glutaminolysis; TCA cycle metabolite and glutamate accumulationProvides energy and precursors for collagen synthesis[58]TGF‑β → Drp1 ↑ → excessive mitochondrial fission → ROS ↑ → HIF‑1α ↑ → Fasn ↑Excessive fission and ROS; upregulation of lipogenic genesfibroblast proliferation, ECM deposition[59]MCU ↑ → mitochondrial Ca2+ overload → mtROS ↑ → p38/ATF‑2/CREB → PGC‑1α → CPT1A ↑ ; MCU → BCL‑2 ↑ → CPT1A‑BCL‑2 anti‑apoptotic complexEnhanced fatty acid oxidation; mitochondrial dysfunction; apoptosis resistanceMacrophage apoptosis resistance, pro‑fibrotic phenotype, ECM deposition[60]TGF‑β → mTOR → ETC subunits ↑, OXPHOS enhancedEnhanced OXPHOS and glycolysis for ATP supply; TCA metabolite accumulationα‑SMA activation, fibroblast activation, collagen synthesis, ECM deposition[61]CTGF → NOX4 → ROS burst → PGC‑1α/NRF1 → OXPHOS & FAO ↑Simultaneous upregulation of OXPHOS and FAODamaged material accumulation, promote apoptosis[62]Macrophage miR‑33 ↑ → PGC‑1α suppression → mitochondrial dysfunctionImpaired OXPHOS and autophagy; ATP instabilityMetabolic disorder accelerates IPF[63]MCU ↑ → Ca2+ overload → mPTP opening, Cyt c/Smac release → caspase‑9/‑3 cascadeBlocked TCA cycleOxidative damage, inflammatory response, apoptosis, cell death[64]Endoplasmic reticulumER stress → macrophage exosome release carrying HK2, LDHADirect transfer of glycolytic enzymes, enhancing glycolytic fluxPromotes fibroblast activation, proliferation, and IPF progression[22, 65]IRE1α‐mediated ER stress → AT2 transition to DATP state; ATF4‐Chop axis → Caspase‐12 activationDATP reliance on glycolysis; lactate accumulationPromotes AT2 apoptosis, impairs repair, drives granulocyte recruitment[22, 66]TXNDC5 ↑ → binds TGFBR1 → enhances TGF‐β1 signaling → PI3K/Akt/mTOR → ATF4 inductionmTOR/ATF4‐driven serine‐glycine metabolic reprogrammingPromotes myofibroblast differentiation and IPF progression[67, 68]Dysregulated AA metabolism → PGF2α, 5‑HETE, LTB4 production ↑Increased synthesis of pro‑inflammatory lipid mediatorsFibroblast proliferation and collagen deposition; neutrophil activation, inflammation, exacerbation of PF[69]TSP‑1 ↑ → CD47/ROS/ERS → UPR activation; ATF3 → PINK1; ERS‑ROS vicious cycleUPR‑driven ROS generation; PINK1‑mediated mitochondrial damageExacerbates pulmonary fibrosis, mitochondrial dysfunction, autophagy dysregulation[50, 51]LysosomeDACT2 ↓ → impaired lysosomal degradation of LDHA and glycogen; TGF‑β/Smad2 activationSustained glycolysis; increased lactate and glycogen metabolismDrives collagen deposition and α‑SMA expression[70]BAG3 ↑ → LC3B‑II/p62 accumulationEnhanced autophagic clearance; impaired autophagic flux in IPFExcessive autophagy causes cell death; impaired autophagy causes fibrotic remodeling[71]PeroxisomeTGF‐β → ERS → TFEB‐mediated autophagy ↑; ERO1A ↑ → COL1A1‐SSG ↑Amino acid release from autophagic degradation; oxidative modification of collagenSupplies collagen substrates; stabilizes collagen, resists degradation, increases ECM stiffness, drives irreversible IPF[22, 72]SIRT6 ↓ → PPARα signaling ↓ → reduced FAO genes (Cpt1a, Acox1); impaired peroxisomal‑mitochondrial couplingDecreased fatty acid oxidation; reduced lipid contentLoss of AT2 self‑renewal capacity, AT2 progenitor depletion, enhanced inflammation, PF[22]TGF‑β/Smad3 → PEX13 ↓; ACOX1, ABCD3, CAT, SOD1, HO‑1, GR, Nrf2 ↓Weakened ROS detoxification; downregulated peroxisomal metabolismImbalanced antioxidant responses; vicious cycle of ROS and fibrosis[73]John Wiley & Sons, Ltd. Major organelles involved in metabolic reprogramming during idiopathic pulmonary fibrosis and their underlying molecular mechanisms. Activation of Glycolytic Promotes Collagen Deposition The transition of quiescent fibroblasts into collagen‐secreting myofibroblasts requires a metabolic switch that upregulates glycolysis and its rate‐limiting enzymes. Consistent with this model, recent work emphasizes that metabolic reprogramming promotes the transition from lipofibroblasts to profibrotic myofibroblasts, in part through suppression of TCF21 and PPARγ, while ER‐stress‐associated loss of PGC‐1α further reinforces the fibrotic phenotype [74]. Normally quiescent, glycolytic enzymes are aberrantly activated in IPF by TGF‐β, IL‐11, and HIF‐1α, driving fibrosis through enhanced glycolytic flux and lactate production. In crystalline silica (CS)‐induced IPF, IL‐11 activates the extracellular signal‐regulated kinase (ERK) pathway to enhance HIF‐1α translation and inhibit its degradation, thereby upregulating HIF‐1α‐dependent glycolytic enzymes hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) to promote fibroblast‐to‐myofibroblast transition (FMT) and collagen deposition. HK2, located on the outer mitochondrial membrane, utilizes mitochondrially exported ATP to phosphorylate glucose, thereby driving glycolysis and inhibiting mitochondrial apoptosis. As a result, silencing IL‐11 is able to block the ERK–HIF‐1α axis, reverse enhanced glycolysis, and ultimately alleviate IPF [55]. TGF‐β rapidly upregulates the key glycolytic enzyme fructose‐2,6‐bisphosphatase 3 (PFKFB3) in myofibroblasts via Smad2/3 and synergizes with rate‐limiting enzymes like phosphofructokinase 1 (PFK1) and HK2 to enhance glycolysis in myofibroblasts. In lung tissues and myofibroblasts of patients with IPF, PFKFB3/PFK1/HK2 expression is positively correlated with alpha‐smooth muscle actin (a‐SMA) expression, indicating a direct link between glycolytic reprogramming and the fibrotic phenotype. Moreover, both TGF‐β and HIF‐1α promote fibrosis by increasing glucose uptake, transporter expression, and activating serine‐glycine and HK2 pathways [65] (Figure 3). Metabolic reprogramming driven by organelle crosstalk in idiopathic pulmonary fibrosis (IPF). Glucose metabolism is rewired toward glycolysis through the activation of glycolytic enzymes by mitochondrial IL‐11/extracellular signal‐regulated kinase 1/2 (ERK1/2)–hypoxia‐inducible factor 1 alpha (HIF‐1α), transforming growth factor‐beta (TGF‐β)/Smad, and endoplasmic reticulum(ER) stress signaling. Lactate accumulation further induces AT2‐cell apoptosis via the transcription factor 4 (ATF4)‐C/EBP homologous protein (CHOP)–caspase‐12 axis. Lipid metabolism is altered by mitochondrial calcium uniporter (MCU)‐mediated increases in mitochondrial reactive oxygen species (mtROS), which upregulate lipid metabolic genes and cooperate with element‐binding protein (CREB) to activate the p38 mitogen‐activated protein kinase (p38 MAPK)/ATF2 pathway, leading to carnitine palmitoyltransferase 1A (CPT1A) upregulation. MCU also elevates B‐cell lymphoma 2 (BCL‐2). BCL‐2 is located at the mitochondrial membrane with CPT1A to promote fatty acid oxidation (FAO) and inhibit mitochondrial permeability transition pore (mPTP) opening. Amino acid metabolism is modulated by TGF‐β–mTOR–ATF4 pathway which can upregulate endoplasmic reticulum oxidoreductin 1 alpha (ERO1A) and COL1A1. ER stress can upregulate transcription factor EB (TFEB) to enhance autophagy, while the SMAD3–p38 MAPK pathway further makes contribution to the inhibition of collagen degradation and provides precursors for collagen synthesis, collectively facilitating fibrotic extracellular matrix accumulation. Enhanced glycolysis accumulates succinate, which inhibits prolyl hydroxylase (PHD) to stabilize HIF‐1α. Subsequently, HIF‐1α can be combined with the promoters of glycolytic enzyme genes such as PFKFB3 and HK2. It forms a positive feedback loop that promotes glycolysis and enhances the expression of α‐SMA, collagen, and fibronectin. The glycolytic inhibitor 2‐deoxyglucose (2‐DG) effectively blocks FMT and collagen deposition [75] (Figure 3). Additionally, ER stress will induce macrophages to release exosomes, enhancing their interaction with fibroblasts [22]. Exosomes (30–150 nm vesicles) mediate local and long‐distance intercellular communication [76]. Macrophage‐derived exosomes carry HK2 and LDHA, directly enhancing fibroblast glycolysis, ATP and lactate production, and collagen synthesis, while ER stress further triggers fibroblast activation, differentiation, and proliferation to promote IPF. Exosomal components will promote metabolic reprogramming and enhance the expression of genes involved in glycolysis and fibroblast differentiation into myofibroblasts. Regulatory Factors of Glycolysis: CBX5 and DACT2 Epigenetic regulator chromobox protein homolog 5 (CBX5) promotes FMT by remarkably upregulating the expression of pro‐fibrotic genes such as collagen triple helix repeat containing 1 (CTHRC1) and collagen type I alpha 1 chain (COL1A1), while reducing anti‐fibrotic metabolic genes like PPARα/PPARγ. On the contrary, CBX5 silencing can block TGF‐β‐driven glycolytic metabolism and enhance AMPK‐mediated mitochondrial oxidative metabolism, thereby inhibiting collagen secretion [75]. Therefore, targeting CBX5 may break the vicious cycle between metabolic reprogramming and fibroblast activation, which offers a new therapeutic strategy for IPF. Dysregulation of Dishevelled‐binding antagonist of β‐catenin 2 (DACT2) has a synergistic effect with glycogen metabolism to regulate IPF. The overexpression of DACT2 can inhibit collagen deposition and α‐SMA expression induced by bleomycin or TGF‐β1. In IPF patients, the expression of DACT2 significantly decreases. Mechanistically, DACT2 inhibits glycolytic activity, reduces glucose uptake and lactate production, and blocks TGF‐β/Smad2 signaling by promoting lysosomal degradation of LDHA. Another study shows that by promoting LDHA degradation, DACT2 also indirectly reduces glycogen metabolism, which drives N‐linked glycan synthesis and fibrosis [70]. Lactate Signaling and Exosome‐Mediated Intercellular Propagation Beyond its role as a terminal metabolite of glycolysis, lactate directly signals to drive fibroblast activation and IPF progression. In myofibroblasts stimulated by TGF‐β, the upregulation of monocarboxylate transporter 4 (MCT4) facilitates lactate export, leading to extracellular lactate accumulation and local acidification. This acidic microenvironment promotes the proteolytic activation of latent TGF‐β from the extracellular matrix, which establishes a self‐amplifying loop that perpetuates fibrotic signaling independently of de novo TGF‐β synthesis. Furthermore, lactate acting as a substrate for histone lactylation is an emerging epigenetic modification that directly links metabolic reprogramming to transcriptional regulation [77]. In pulmonary fibroblasts, lactate‐derived histone lactylation at the promoters of key pro‐fibrotic genes, including transforming growth factor beta 1 (TGFβ1), actin alpha 2 (ACTA2), and COL1A1, facilitates their sustained expression and stabilizes the myofibroblast phenotype. Extracellular lactate also activates GPR81 (HCAR1), triggering ERK and Smad pathways to promote α‐SMA and collagen synthesis, thereby bypassing TGF‐β receptor engagement [78]. Apoptosis of Alveolar Type II (AT2) Cells Apoptosis of AT2 cells leads to alveolar epithelial injury and impaired repair processes, and is currently considered one of the main causes of IPF. Long‐term disruption of intrinsic protein homeostasis causes AT2 cells to lose their typical characteristics and develop a reprogrammed cellular state that drives lung injury. Inhibiting IRE1α signaling transduction can attenuate this reprogramming and reduce AT2 cells‐driven granulocyte recruitment and pulmonary fibrosis [66]. In ER stress, injury‐transient alveolar progenitors (DATPs) can regulate fibrosis. Specifically, IRE1α, as a mediator of ER stress, promotes the transition of cells to the DATP state [22]. DATPs rely on glycolysis for energy supply, lactate may accumulate, promoting TGF‐β1 release leading to dysfunction of lung epithelial progenitor cells and establishing a microenvironment for IPF. Lactate activates caspase‐12 via the ATF4–CHOP axis to induce AT2 apoptosis, a process blocked by ER stress inhibitors (Figure 3). Disruption of Amino Acid Metabolic Homeostasis Promotes Collagen Synthesis Driving Pulmonary Fibrosis Amino acid metabolism is integral to cellular homeostasis, providing not only the building blocks for protein synthesis but also precursors for nucleotides, lipids, and key metabolites such as glutathione. In the healthy lung, fibroblasts maintain a low rate of amino acid turnover, synthesizing only the modest amounts of collagen and other ECM components required for normal tissue maintenance. In IPF, however, this homeostatic balance is fundamentally disrupted (Table 1). In IPF fibroblasts, ATF4 and mTOR target genes are significantly upregulated. mTOR stimulation can regulate ATF4 translation, promoting ECM deposition [57]. ATF4 is able to increase serine/glycine synthesis enzymes (serine hydroxymethyltransferase 2, SHMT2) and asparagine synthetase (ASNS) to disrupt amino acid metabolic homeostasis, which promotes de novo glycine synthesis to ensure the supply of collagen precursors [56]. ATF4 also regulates amino acid transporters and aminoacyl‐tRNA synthetases to sustain amino acid supply in IPF. Notably, the inhibition of mTOR not only leads to the loss of ATF4 target gene expression but also reduces glycolytic enzymes, thereby regulating glycolysis and TCA cycle metabolites [57]. The ER protein thioredoxin domain‐containing protein 5 (TXNDC5) is highly upregulated in IPF and bleomycin (BLM) models, directly binding transforming growth factor β receptor 1 (TGF‐β‐R1) to enhance TGF‐β1 signaling and promote fibrosis [67]. Subsequently, the PI3K/AKT/mTOR signaling pathway under TGF‐β1 stimulation is involved in the progression of pulmonary fibrosis. mTOR and ATF4 are important regulators of serine‐glycine metabolic reprogramming in myofibroblasts. Mechanistically, PI3K inhibition prevents ATF4 induction and downstream signaling [68] (Figure 3). Furthermore, TGF‐β1‐induced the Smad family member 3 (Smad3)/p38 mitogen‐activated protein kinase (MAPK) pathway, which promotes glutaminolysis by upregulating kidney‐type glutaminase (KGA)/glutaminase C (GAC) isoforms of glutaminase 1 (GLS1), accumulating TCA metabolites and glutamate to supply energy and precursors for collagen synthesis [58]. Exogenous supplementation of glutamate or alpha‐ketoglutarate (α‐KG) can reverse the differentiation inhibition caused by GLS1 deficiency, confirming glutaminolysis as a key fibrotic regulator. Additionally, TGF‐β can upregulate transcription factor EB (TFEB)‐mediated autophagy via ER stress, degrading misfolded proteins to release amino acids for collagen synthesis [22]. Furthermore, glutathione (GSH) serves an important regulatory function in amino acid metabolism. Exposure of fibroblasts to TGF‐β causes an increase in endoplasmic reticulum oxidoreductin 1 alpha (ERO1A), which leads to the elevation of S‐glutathionylated collagen type I alpha 1 chain (COL1A1‐SSG). The oxidative modification of COL1A1 is synergistic with the ER oxidative stress, and it prevents collagen degradation [72]. This oxidative modification enhances COL1A1 stability, promoting dense collagen networks that increase ECM stiffness and drive irreversible IPF (Figure 3). Lipid Metabolic Reprogramming Drives Pulmonary Fibrosis Lipid metabolism refers to the synthesis and degradation of lipid molecules such as fatty acids, triglycerides, and cholesterol within cells. It serves not only as a vital source of energy but also constitutes a core process for the construction of biological membrane structures and the production of signaling molecules. Impaired Lipid Metabolism in AT2 Cells Disrupts Surfactant Synthesis and Self‐Renewal AT2 cells rely heavily on lipid metabolism to maintain the synthesis and secretion of alveolar surfactant, while also ensuring cell membrane integrity and responding to oxidative stress damage. AT2 cells rely on stearoyl‐CoA desaturase 1 (SCD1) in ER, which converts saturated fatty acids to unsaturated forms [79]. It is indispensable for unsaturated fatty acids to maintain ER homeostasis in lung epithelial cells. Moreover, increasing their production can reduce ER stress and alleviate fibrotic remodeling in mouse lungs. Under fibrotic injury, impaired lipid synthesis in AT2 cells reduces phospholipid supply, preventing proper packaging of surfactant proteins into transport vesicles and causing their accumulation and misfolding in the ER. It also directly impairs surfactant protein folding, leading to ER retention. Ultimately, all these factors exacerbate ER stress. In IPF, events of AT2 cells progenitor depletion and reduced AT2‐cell renewal capacity exist. Lipid biosynthesis and FAO are downregulated in IPF lungs and AT2 cells, reducing lipid content. Lipid metabolism, and FAO in particular, is essential for AT2 self‐renewal, providing energetic substrates for proliferation and differentiation. Peroxisome proliferator‐activated receptor alpha (PPARα) is the master transcriptional activator of FAO genes such as carnitine palmitoyltransferase 1A (CPT1A) and acyl‐CoA oxidase 1 (ACOX1). However, PPARα expression declines sharply after BLM treatment, suggesting that loss of this FAO program contributes to AT2‐cell dysfunction. Sirtuin 6 (SIRT6), a nicotinamide adenine dinucleotide (NAD+)‐dependent deacetylase with anti‐aging, immune, and metabolic functions, is highly expressed in AECs. Mechanistically, it counteracts BLM‐triggered secretion of IL‐1β, IL‐6, and TNF‐α through PPARα, restores IL‐10 levels, and inhibits BLM‐induced pulmonary fibrosis and AT2‐cell apoptosis [22]. SIRT6 enhances lipid metabolism and reduces oxidative stress, highlighting the SIRT6–PPARα axis as a potential therapeutic target. DRP1‐Driven Mitochondrial Fission Promotes Fibroblast Lipogenesis and Macrophage Apoptosis Resistance DRP1, the core mitochondrial fission protein, is abnormally activated in IPF lung fibroblasts and promotes FMT, with its expression positively correlated with TGF‐β signaling. Under TGF‐β stimulation, upregulated DRP1 causes excessive mitochondrial fission, significantly increasing ROS levels, thereby activating HIF‐1α, which synergistically upregulates lipid synthesis genes (fatty acid synthase, FASN), causing lipid metabolic imbalance [59]. Inhibiting DRP1 significantly increases MCU expression. This leads to mitochondrial calcium overload which will then cause membrane potential collapse, inhibit OXPHOS, and increase mitochondrial reactive oxygen species (mtROS) generation. Notably, this mtROS surge can activate the p38 MAPK axis through a redox‐dependent mechanism to promote activating transcription factor 2 (ATF2) phosphorylation. Subsequently, phosphorylated ATF‐2 will synergize with cAMP response element‐binding protein (CREB) to enhance peroxisome proliferator‐activated receptor gamma coactivator 1 alpha (PGC‐1α) transcription. Finally, the key fatty acid oxidation enzyme CPT1A will be upregulated and lipid metabolic reprogramming will be driven [80]. In addition, the MCU upregulates BCL‐2 expression by regulating calcium homeostasis. CPT1A binds to the BH3 domain of BCL‐2, forming an anti‐apoptotic complex anchored to the mitochondrial membrane, which enhances macrophage apoptosis resistance caused by fatty acid oxidation (FAO) and promotes a pro‐fibrotic phenotype characterized by ECM deposition [60]. Therefore, knocking out BCL‐2 or using the inhibitor ABT‐199 can restore apoptosis sensitivity and reverse fibrosis, while inhibiting CPT1A activity can disrupt the CPT1A–BCL‐2 interaction. Palmitate Lipotoxicity and Eicosanoid Metabolites Drive Fibroblast Activation and Inflammatory Amplification Upregulation of lipogenic genes promotes the production of palmitic acid (PA). While PA is a non‐essential fatty acid that serves physiological roles in membrane synthesis and protein palmitoylation, its excessive accumulation under sustained profibrotic stimulation becomes lipotoxic. Elevated PA can induce the formation of NLRP3 inflammasomes [81]. On one hand, NLRP3 promotes the generation of inflammatory mediators such as IL‐1β and IL‐18. On the other hand, NLRP3 drives fibroblast proliferation and ECM deposition. Moreover, PA can induce ER stress via CD36 and simultaneously promote apoptosis of AT2 cells. By promoting intracellular lipid accumulation, CD36 can also increase ROS production and induce inflammatory responses. Linoleic acid generates arachidonic acid (AA) in the ER. AA is a polyunsaturated fatty acid which can be converted into prostaglandins (PG) via the cyclooxygenase (COX‐1) pathway or leukotrienes (LT) via the 5‐lipoxygenase (5‐LOX) pathway, respectively [82]. Dysregulation of PG and LTs has been identified as involved in the development of pulmonary fibrosis. Specifically, prostaglandin F2α (PGF2α) is an endogenous compound associated with inflammation and oxidative stress, which mediates a series of inflammatory diseases [83]. Additionally, PGF2α acts on its homologous receptor, the prostaglandin F receptor (FP), stimulating the proliferation of lung fibroblasts and collagen production that results in the deposition of ECM. 5‐lipoxygenase (LOX5) converts AA into 5‐hydroperoxyeicosatetraenoic acid (5‐HPETE), which is then further reduced to 5‐hydroxyeicosatetraenoic acid (5‐HETE). 5‐HETE is associated with acute inflammation, allergy, and tumorigenesis. Additionally, 5‐HETE can be converted into leukotriene B4 (LTB4) [84]. Both 5‐HETE and LTB4 can activate neutrophils, which results in the release of inflammatory mediators and promotes the exacerbation of pulmonary fibrosis [69] (Figure 3). ROS Burst Leading to Organelle Dysfunction Drives Pulmonary Fibrosis ROS are partially reduced oxygen derivatives that serve dual roles in cellular physiology. At low to moderate levels, ROS function as essential signaling molecules, regulating proliferation, differentiation, and adaptive stress responses. Redox homeostasis is maintained by an elaborate antioxidant defense network distributed across mitochondria, peroxisomes, and the ER. In IPF, however, this redox equilibrium collapses. The resulting ROS burst inflicts direct damage on mtDNA, triggers ER stress, impairs lysosomal autophagy, and further disables peroxisomal ROS detoxification, establishing a self‐perpetuating cycle of organelle dysfunction that relentlessly drives fibroblast activation, myofibroblast differentiation, and irreversible fibrotic remodeling (Table 1). Redox Imbalance: TGF‐β Disrupts Mitochondrial and Peroxisomal ROS Detoxification In myofibroblasts, OXPHOS is inhibited via TGF‐β signaling, reducing mtDNA stability and causing its leakage extracellularly [61]. The released mtDNA directly activates fibroblast α‐SMA expression. Activated fibroblasts require abundant ATP for collagen synthesis and ECM deposition. TGF‐β can enhance ETC through activation of the mTOR signaling pathway to provide ATP for collagen synthesis and cell activation, and cause accumulation of TCA cycle metabolites. The TCA cycle metabolites provide reducing equivalents, such as nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), to the ETC, while mTOR independently upregulates ETC complex subunits and activates glycolysis to boost energy supply. At this point, mitochondrial homeostasis is disrupted, disturbing the OXPHOS process and inducing the production of ROS. Furthermore, TGF‐β can also directly promote ROS production by activating NADPH oxidases. Moreover, through the Smad pathway, stimulating fibroblasts with TGF‐β downregulates peroxisomal proteins such as PEX13, ACOX1, ATP‐binding cassette subfamily D member 3 (ABCD3), catalase (CAT), which weakens the ability of peroxisomes to inhibit ROS [43]. Meanwhile a series of antioxidant enzyme activities decrease, such as superoxide dismutase 1 (SOD1), heme oxygenase 1 (HO‐1), glutathione reductase (GR), and NRF2 [73]. As a result, antioxidant responses are imbalanced, promoting the accumulation of inflammatory mediators. Furthermore, the downregulation of peroxisomes further leads to the release of pro‐fibrotic factors TGF‐β, COL1A2, and IL‐6 and the activation of collagen proteins [73], promoting ROS formation and creating a vicious cycle that allows fibrosis to progress continuously. Activator protein 1 (AP‐1) mediates ROS‐dependent TGF‐β1 activation and IL‐6 production, and participates in TGF‐β1‐mediated PEX13 downregulation [73]. As PEX13 is a direct target of TGF‐β–Smad signaling transduction, Smad3 can directly bind to the promoter region of PEX13, suppressing peroxisomal metabolism through activation of TGF‐β signaling transduction [43]. ROS‐Driven Metabolic Dysregulation In the healthy lung, ROS production and scavenging are balanced, ensuring oxidative signaling without biomolecular damage. ROS is able to inhibit the PI3K–AKT–mTOR pathway and activate AMPK signaling to enhance lysosomal autophagy, which clears damaged organelles and activates antioxidant pathways such as nuclear factor NRF2 and sestrin (SESN) pathway. This process promotes the autophagic degradation of Kelch‐like ECH‐associated protein 1 (Keap‐1) on p62 and stimulates antioxidant responses [85]. Moreover, in IPF AT2 cells and fibroblasts, elevated BAG3 and impaired autophagy are marked by microtubule‐associated protein 1 light chain 3 beta‐II (LC3B‐II) and p62 accumulation, promoting fibrotic remodelin [71] (Figure 4). Reactive oxygen species (ROS)‐mediated interorganellar crosstalk in idiopathic pulmonary fibrosis (IPF) pathogenesis. In mitochondria, transforming growth factor‐beta (TGF‐β) can elevate ROS via connective tissue growth factor (CTGF) and dynamin‐related protein 1 (DRP1). TGF‐β can also disrupt mitochondrial homeostasis through the suppression of peroxisome proliferator‐activated receptor gamma coactivator 1 alpha (PGC‐1α)/nuclear respiratory factor 1 (NRF1) and the activation of poly(ADP‐ribose) polymerase 1 (PARP1). In peroxisomes, ROS induces TGF‐β via activator protein 1 (AP‐1), while TGF‐β reciprocally downregulates peroxisomal antioxidants to establish a self‐amplifying oxidative cycle. In the endoplasmic reticulum, thrombospondin‐1 (TSP‐1) triggers unfolded protein response (UPR) and ROS generation through CD47 signaling, and subsequently promotes PINK1‐dependent mitophagy. However, excessive autophagy leads to cell death. In IPF patients and BLM‐induced mouse models, silent information regulator 2 homolog 1 (SIRT1) expression is significantly reduced. Mitochondrial ROS inhibits SIRT1 activity by activating poly (ADP‐ribose) polymerase 1 (PARP1) to consume NAD+, which leads to defective mitophagy and mtDNA damage in a vicious cycle [86]. Connective tissue growth factor (CTGF) belongs to the CCN family and is a cysteine‐rich secreted matricellular protein. CTGF is a downstream mediator ofmitophagy in AECs and can be induced by TGF‐β. NADPH oxidase 4 (NOX4) is activated by CTGF to induce mitochondria to produce ROS and disrupt mitophagy [87]. In the process of asbestos‐exposed pulmonary fibrosis, mitochondrial NOX4 in macrophages specifically localizes to the mitochondrial matrix via the transmembrane transport mechanism of the translocase of the inner mitochondrial membrane 23 (TIM23) complex. This interaction drives mitochondrial ROS burst and activates the PGC‐1α/NRF1 axis to simultaneously upregulate OXPHOS and FAO, thereby accelerating IPF [62]. Conversely, it is worth noting that high macrophage microRNA‐33 (miR‐33) expression in IPF suppresses PGC‐1α and other targets, causing mitochondrial and metabolic dysfunction. In contrast, miR‐33 deficiency restores PGC‐1α expression, enhancing mitochondrial respiratory capacity, ATP generation, and autophagic activity [63]. This mechanism suggests that targeting miR‐33 can reverse the fibrotic process by regulating macrophage metabolism, providing a new direction for pulmonary fibrosis treatment. MCU is significantly upregulated in IPF lung macrophages, leading to mitochondrial calcium overload that contributes to fibrosis pathogenesis. Structurally, excessive Ca2+ opens the mitochondrial permeability transition pore (mPTP), disrupting the proton gradient and inhibiting ATP synthesis. Simultaneously, it causes osmotic imbalance, rupture of mitochondrial cristae structure, and disorganization of ETC complex spatial arrangement. This triggers the massive production of ROS. This further damages mitochondrial calcium transport proteins, inhibits Ca2+ efflux, and accelerates cellular oxidative damage. Metabolically, high Ca2+ concentrations block the TCA cycle, reducing NADH supply and exacerbating the energy crisis. Furthermore, after mitochondrial membrane permeability increasing, pro‐apoptotic factors such as cytochrome c (Cyt c) and second mitochondria‐derived activator of caspases/direct inhibitor of apoptosis‐binding protein with low pI (Smac/DIABLO) can be released into the cytosol to activate the caspase‐9/‐3 cascade reaction and trigger the classical apoptotic pathway, inflammation, and cell death [64]. Organelle‐Targeted Therapeutic Interventions in Pulmonary Fibrosis Given the established role of organellar damage in IPF metabolic reprogramming, restoring organelle homeostasis represents a novel therapeutic paradigm. Numerous methods‐including those targeting mitochondria, ER, lysosomes, and peroxisomes, as well as organelle‑specific metabolic reprogramming therapies, have been developed and summarized below. Therapeutic Restoration of Organelle Homeostasis Mitochondria‐Targeted Antioxidants Antioxidants represent a promising therapeutic strategy for IPF by restoring mitochondrial homeostasis. Antioxidants are covalently conjugated to triphenylphosphonium cations (TPP) via chemical bonds, utilizing TPP as a mitochondrial targeting vector to achieve specific delivery of antioxidants to the mitochondrial matrix. Mitochondrial vitamin E (MVE), mitochondrial TEMPO (Mito‐TEMPO), and mitochondrial coenzyme Q (MitoQ) are the most commonly used TPP‐modified redox agents for the treatment of lung diseases [88]. MVE can inhibit mitochondrial ROS‐dependent activation of pulmonary fibroblasts and suppress extracellular matrix deposition. Mito‐TEMPO can alleviate alveolar epithelial cell senescence. MitoQ can stabilize mitochondrial DNA in AECs. However, MitoQ may reduce MMP, paradoxically inducing oxidative stress. A study has developed polymeric microparticles cloaked by macrophage apoptotic body membranes (MABM), with an outer layer coated in a colony‐stimulating factor shell that is cleavable by matrix metalloproteinase‐9 (MMP‐9), for the delivery of superoxide dismutase (SOD) and catalase (CAT) nanocomplexes (C‐cMAB/NC) [89]. MMP‐9 can degrade the shell, allowing C‐cMAB/NC to reach deeper alveoli, while the MABM coating exhibits high affinity for AECs. It can scavenge ROS, thereby effectively restoring mitochondrial homeostasis, reducing epithelial cell loss, and alleviating lung injury. Targeting Mitochondrial Dynamics: Fission and Mitophagy Mdivi‐1, a selective inhibitor of DRP1 assembly, blocks pathological mitochondrial fission to inhibit fibroblast proliferation and prevent stress‐induced epithelial apoptosis, thereby alleviating IPF progression. Furthermore, restoration of mitochondrial autophagy in lung macrophages has been found to successfully convert lung macrophages from a pro‐fibrotic phenotype to an anti‐fibrotic phenotype. Studies have developed mitochondrial autophagy‐enhancing nanoparticles (MENs) through encapsulation of Parkin mRNA [90]. Co‐delivery of MENs with healthy mitochondria restores mitochondrial homeostasis and significantly ameliorates pulmonary fibrosis. Mitochondrial Replacement Therapies Mitochondrial replacement therapy (MRT) can directly restore redox homeostasis by supplementing dysfunctional mitochondria with exogenous ones, which is one of the most promising approaches. However, isolated mitochondria rapidly degrade extracellularly and may act as damage‐associated molecular patterns (DAMPs), exacerbating inflammation. Novel methods for intercellular mitochondrial transfer improve these limitations. Mesenchymal stem cells (MSCs) can serve as ideal cellular carriers for selectively delivering mitochondria to damaged AECs [91]. However, the low energy demand of mesenchymal stem cells (MSCs) often limits their mitochondrial biogenesis, thereby restricting the number of mitochondria available for transfer and adversely affecting therapeutic efficacy. Therefore, providing an efficient and sustained mitochondrial supply to damaged lung epithelial cells is essential for restoring their mitochondrial bioenergetics. Studies have found that precise treatment of human mesenchymal stem cells (hMSC) derived from the human placenta with pioglitazone (Pg) can effectively activate mitochondrial biogenesis in hMSCs primarily through the PGC‐1α‐NRF1‐TFAM pathway. Furthermore, the combined engineering technology (Pg‐Fe‐hMSC), which integrates platinum (Pt) treatment with iron oxide nanoparticle (IONPs) stimulation, enables the efficient and sustained delivery of engineered hMSCs to intercellular mitochondria, which we refer to as high‐efficacy hMSCs. The high therapeutic potential of highly differentiated hMSCs has been demonstrated in fibrosis models and humanized multicellular lung spheroid models [92]. Currently, intercellular mitochondrial transfer involves two primary mechanisms. The contact‐dependent pathway requires physical contact between donor and recipient cells, including tunneling nanotubes (TNTs) and connexin 43 (Cx43)‐mediated gap junction channels (GJCs). The contact‐independent pathway enables long‐distance mitochondrial transfer between cells via the release of free mitochondria or encapsulation of mitochondria within extracellular vesicles (EVs). However, exosome‐mitochondrial complexes inherently suffer from low yields and heterogeneous content. To overcome these limitations, healthy mitochondria can be artificially encapsulated into nanocarriers to mimic the functional and nanoscale properties of EV‐mitochondrial complexes [88]. Further research can focus on these two mechanisms to enhance intercellular mitochondrial transfer. ER‐Targeted Strategies When the ER is damaged, the processes of protein folding and post‐translational modification are disrupted, leading to ER stress, which is a key factor in the occurrence and development of pulmonary fibrosis. Small‐molecule chemical chaperones 4‐phenylbutyric acid (4‐PBA) and tauroursodeoxycholic acid (TUDCA) are currently the most extensively studied intervention drugs. Both exert their anti‐fibrotic effects by non‐specifically stabilizing protein conformation and alleviating the burden of unfolded proteins [93]. In addition, small‐molecule integrated stress response inhibitor (ISRIB) targets downstream PERK effectors, selectively antagonizing the binding of phosphorylated eukaryotic translation initiation factor 2 alpha (eIF2α) to eukaryotic translation initiation factor 2B (eIF2B), stabilizing the active conformation of the guanine nucleotide exchange factor, and restoring the translation synthesis of downstream proteins under sustained ER stress [94]. Kinase inhibitor of RNase attenuator (KIRA) inhibits the RNase activity of IRE1α by stabilizing the ATP‐binding kinase domain and preventing oligomerization [95]. These therapeutic agents have demonstrated significant effects in counteracting ER stress and stabilizing ER function. However, their efficacy in pulmonary fibrosis models remains understudied and requires further experimental validation. Secreted phosphoprotein 1 (SPP1) is a membrane‐integrated protease closely related to the ER, with its function, localization, and regulatory mechanisms directly associated with protein processing in the ER. In vitro conditions, SPP1 inhibits the proliferation, migration, and promotes apoptosis of M2 macrophages. Hence, it possibly indirectly inhibits fibrosis by weakening the pro‐fibrotic functions of M2 macrophages [96]. Lysosomal Restoration In terms of lysosomal repair, the disaccharide trehalose is currently the most extensively studied lysosomal autophagy activator in preclinical evidence. It activates the TFEB transcriptional program through an mTOR‐independent mechanism, which not only enhances autophagic degradation and improves lysosomal acidification deficiency and dysfunction, but also indirectly facilitates the clearance of damaged mitochondria. Furthermore, TFEB is the master gene regulating lysosomal biogenesis. Under normal conditions, TFEB resides in the cytoplasm. When cells require clearance of damaged components, it translocates to the nucleus to initiate a series of gene expressions. Its enhanced expression may be beneficial for patients with pulmonary fibrosis, as it not only possesses the ability to induce lysosomal biogenesis but also has the potential to enhance mitochondrial autophagy by maintaining the autophagy‐lysosomal pathway. Introducing exogenous genes via TFEB gene transfer constitutes a therapeutic strategy. This can enhance TFEB transcriptional expression, induce lysosomal biogenesis, which in turn enhances autophagy and reduces the burden of fibrotic lesions [16]. Overexpression of vacuolar ATPase B2 subunit (V‐ATPase B2) increases lysosomal acidification, lysosomal enzyme activity, collagen degradation and simultaneously stabilizes the lysosomal membrane. It inhibits cathepsin D leakage and cell death under H2O2‐induced oxidative stress [97]. Furthermore, B2 overexpression enhances the capacity of macrophages to devour collagen. In short, it provides a new strategy for anti‐fibrotic therapy targeting lysosomal homeostasis by synergistically enhancing antioxidant damage resistance in AECs and collagen clearance in macrophages. Similarly, Hirsutella sinensis mycelium (HSM), localized in macrophages, inhibits toll‐like receptor 4 (TLR4) and NF‐κB p65 phosphorylation (p‐p65) in macrophages, downregulating LC3B‐II/LC3B‐I and autophagy related 5 (ATG5), reducing autophagosome numbers, and causing p62 accumulation [98]. It indicates blocked autophagic flux and inhibition of excessive autophagy in macrophages. HSM alleviates the release of pro‐fibrotic factors caused by abnormal autophagy by inhibiting the TLR4/NF‐κB signaling pathway. It is worth mentioning that silica exposure may suppress the mTOR pathway, increase ATG5, Beclin1, and the LC3B‐II/I ratio, which causes overproduction of autophagosomes. Concurrently, the expression of lysosomal membrane marker LAMP1 reduces and lysosomes decline in numbers, causing lysosomal membrane burst and accumulation of p62 which causes lysosomal functional failure. Growth arrest‐specific 6 (Gas6)/Mer tyrosine kinase (Mer) deficiency significantly reduces autophagosome accumulation and P62 aggregation through restoration of the mTOR signaling, inhibition of autophagosome formation (ATG5/Beclin1), and LAMP1, thereby blocking pro‐fibrotic signals like NF‐κB [99]. Peroxisome‐Targeted Strategies Direct repair of peroxisomes in pulmonary fibrosis is currently relatively limited. It has been found that peroxisome proliferator‐activated receptors (PPARs) play a crucial physiological role in immune responses. Activation of PPARs can attenuate pro‐inflammatory mediators, exert anti‐inflammatory effects, and play an important role in anti‐fibrosis. PGC‐1α is a key transcriptional co‐activator of PPARs. PPAR agonists were developed for the treatment of diabetes and hyperlipidemia and may have potential for the treatment of chronic lung diseases. Rosiglitazone treatment increases PGC‐1α expression and alleviates fibroblast activation, strongly supporting the correlation between PGC‐1α‐regulated mitochondrial biogenesis and fibroblast activation. Additionally, thyroid hormones and their analogs, such as sobrerol, can rescue AECs from cellular senescence in a PGC‐1α‐dependent manner [100]. Fenofibrate (FF) is a PPARα agonist and hypolipidemic agent. However, studies have found that FF inhibits TGF‐β‐induced myofibroblast differentiation and activation, independent of PPAR‐α activation and mitochondrial respiration impairment [101]. These findings suggest that metabolic modulating drugs, represented by PPAR agonists, hold potential for repurposing in the treatment of pulmonary fibrosis. PGC‐1α may serve as a key node for epithelial cell protection and fibroblast inhibition. Fenofibrate may exhibit a non‐canonical mode of action independent of receptor‐ligand binding, which requires further investigation. Organelle‐Based Therapies Targeting Metabolic Reprogramming IPF is driven by metabolic reprogramming across mitochondria, ER, lysosomes, and peroxisomes, fueling fibroblast activation, AT2‐cell apoptosis, and inflammation. Targeting these organelle‐specific metabolic vulnerabilities thus offers a direct strategy to restore homeostasis and halt fibrosis progression (Table 2). Table 2Overview of metabolic reprogramming therapeutic targets and related mechanism in IPF.Organelle typeTherapeutic targetIntervention strategyMechanismReferencesMitochondriaACSS3Over expression Inhibiting CYP2A, reducing fatty acid oxidation; enhancing glycolysis, increasing lactic acid production, shifting to anaerobic metabolism; inducing mitochondrial dysfunction [102]PCITargeting through IM56 Inhibiting OXPHOS; enhancing protein synthesis and collagen deposition [103]STRT3UpregulationMaintaining mtDNA integrity; reducing mitochondrial autophagy[104]Endoplasmic reticulumHDACsInhibitionInhibiting ERS and EMT[105]LysosomeH‐ferritinCombination with DFOBinding free iron in lysosomes, preventing the Fenton reaction, oxidative membrane damage, and leakage, thereby alleviating lysosomal dysfunction[106]SLC15A3Deletion Reducing ROS levels, modulating OXPHOS; inhibiting M2 polarization of alveolar macrophages and the release of TGF‐β1 [107]PeroxisomePPARγDemethylationRestoring PPARγ expression and inhibiting inflammatory responses.[108]John Wiley & Sons, Ltd. Overview of metabolic reprogramming therapeutic targets and related mechanism in IPF. Inhibiting CYP2A, reducing fatty acid oxidation; enhancing glycolysis, increasing lactic acid production, shifting to anaerobic metabolism; inducing mitochondrial dysfunction Inhibiting OXPHOS; enhancing protein synthesis and collagen deposition Reducing ROS levels, modulating OXPHOS; inhibiting M2 polarization of alveolar macrophages and the release of TGF‐β1 Acyl‐CoA synthetase short‐chain family member 3 (ACSS3) is primarily localized in mitochondria. Unlike ACSS1/2 in the acetyl‐CoA synthetase short‐chain family (ACSS1‐3), ACSS3 plays a key role in propionate metabolism by activating propionate to generate succinyl‐CoA. The expression of ACSS3 is significantly reduced in IPF patients. ACSS3 deficiency reduces fatty acid oxidation by inhibiting carnitine palmitoyltransferase 1A (CPT1A), which leads to lipid droplet accumulation and abnormal lipid metabolism. Simultaneously, it can activate the glycolytic pathway to increase lactate production, which changes cellular energy metabolism towards anaerobic pathways. Mechanistically, ACSS3 deficiency promotes succinyl‐CoA synthesis through the propionate metabolic pathway while reducing acetyl‐CoA and ATP production. This triggers mitochondrial fission‐fusion imbalance, ROS accumulation, and mitophagy inhibition which ultimately results in AT2‐cell apoptosis. In vivo experiments support the therapeutic value of ACSS3 overexpression by showing that ACSS3 can prevent the deposition of ECM and ground‐glass opacities in lung tissue, which alleviates IPF progression as well as can be used as a new therapeutic target [90]. The novel biguanide investigational compound 156 (IM156) selectively inhibits OXPHOS by targeting mitochondrial complex I and it blocks the TGF‐β‐induced metabolic reprogramming in pulmonary fibrosis. Mechanistically, the OXPHOS inhibition induces the energy stress, AMPK phosphorylation, and via this process suppresses the synthesis of proteins. At the same time, it restructures the metabolic network, including increased glycolysis, metabolism of branched‐chain amino acids and ketogenesis, and decreased TCA cycle activity and fatty acid concentrations. The tests in vitro reveal that IM156 can prevent the differentiation of human lung fibroblasts into myofibroblasts and decrease collagen deposition [103]. Sirtuin 3 (SIRT3) is an important member of the sirtuin deacetylase family. It has a complicated regulatory effect in anti‐pulmonary fibrosis. SIRT3 is able to preserve the integrity of mtDNA by deacetylating 8‐oxoguanine DNA glycosylase (OGG1) to prevent mitophagy dysfunction [104]. Histone deacetylases (HDACs) are involved in the regulation of the dynamic balance between acetylation/deacetylation. It has been demonstrated that ER stress and EMT can be induced in lung epithelial cells through HDACs upregulation. HDAC inhibitors have the capacity to silence ER‐stress‐induced epithelial markers and have a significant role in enhancing EMT via PI3K–AKT pathway [105]. Additionally, PGC‐1α can protect against fibrosis with the inhibition of ER stress and reduce the expression of ER stress markers such as phosphorylated IRE1α (p‐IRE1α) and ATF6 in TGF‐β‐treated fibroblasts [109]. Through the breakdown of ferritin, lysosomes release the stored iron so as to maintain intracellular iron homeostasis. Oxidatively exposed under the influence of oxidative stress, H‐ferritin is oxidatively damaged and aggregates, which undergoes degradation in lysosomes through autophagy. The release of the free iron (Fe2+) by lysosomes occurs through the process of ferritinophagy (ferritin autophagy) secured by nuclear receptor coactivator 4 (NCOA4). This Fe2+ forms ROS via the Fenton reaction, which worsens the process of membrane lipid peroxidation, and results in lysosomal leakage. Lysosomal iron and enzymes leaking into the cytosol activate the NLRP3 inflammasome which enhances the release of proinflammatory agents such as IL‐1β [106]. Concurrently, the free iron that goes into cytosol flows into the labile iron pool (LIP) which increases the LIP levels and triggers the EMT transcription factors. Simultaneously, lysosomes transport free iron to mitochondria. The mitochondria overload with iron through mitoferrin 1 (MFRN1) causing ETC dysfunction and ROS burst, which results in an increase in FMT, eventually resulting in excessive extracellular matrix deposition and lung structural remodeling. Furthermore, abnormal accumulation of ferritin‐bound iron within lysosomes leads to sustained production of ROS that stimulates the release of TGF‐β, IL‐11, and other pro‐fibrotic factors via the senescence‐associated secretory phenotype (SASP). Iron chelator deferoxamine (DFO) is able to bind free iron in lysosomes and prevent the Fenton reaction, oxidative damage of the membrane and leakage, alleviating lysosomal dysfunction at its source [106]. The lysosomal membrane transporter solute carrier family 15 member 3 (SLC15A3) is highly expressed specifically in pulmonary macrophages. Its deficiency can significantly alleviate IPF by regulating the oxidative stress. These are achieved through the activation of p62 phosphorylation, NRF2 nuclear translocation, upregulations of antioxidant enzymes like HO‐1 and NAD(P)H quinone dehydrogenase 1 (NQO1), and reducing ROS levels in lung tissue. It also prevents the polarization of alveolar macrophages and the release of TGF‐β1 to inhibit pro‐fibrotic signaling [107]. In peroxisomes of BLM‐induced mice, elevated DNA methyltransferases DNMT1/3a contributes to the hypermethylation of the PPARγ promoter, suppressing PPARγ expression and significantly promoting pulmonary fibrosis development. Conversely, 5‐azacytidine (5‐aza) and gambogic acid (GA) can demethylate and reduce TGF‐β‐induced PPARγ suppression to restore PPARγ loss [108]. Conclusion Organelles play significant roles in the metabolic reprogramming of IPF. In recent years, the roles of organelles have garnered increasing attention. Numerous studies have enhanced our understanding of the underlying mechanisms of IPF progression and provide novel therapeutic targets for IPF. However, the specific molecular mechanisms that can regulate IPF still remain complex. Further researches of organellar metabolic reprogramming in IPF are necessary for new therapeutic strategies. Author Contributions Yining Zhang: conceptualization, methodology, investigation, data curation, visualization, writing – original draft, writing – review and editing. Ling Teng: investigation, validation, writing – review and editing. Limin Gong: investigation, visualization, writing – review and editing. Yuandong Fu: conceptualization, resources, supervision, writing – review and editing. Minyi Qian: conceptualization, methodology, project administration, supervision, validation, writing – review and editing. Conflicts of Interest The authors declare no conflicts of interest.